A consortium of investors led a $75.5 Series B round in PlateletBio.

A consortium of investors, including SymBiosis, K2 HealthVentures, Oxford Finance, Ziff Capital Partners and Qiming Venture Partners, led a $75.5 Series B round in PlateletBio, a preclinical-stage biotechnology company. “This is a major milestone for PlateletBio, adding capital and resources needed to advance our innovative platelet-like cell therapy science and manufacturing platform and support key corporate initiatives over the next 18-24 months,” Sam Rasty, PlateletBio President and Chief Executive Officer.